Experts from Europe’s major health data initiatives met virtually to discuss how the European Genomic Data Infrastructure is supporting partner projects, and why sustained collaboration is central to Europe’s wider health and research data ambitions.

Europe’s Genomic Data Infrastructure showcases cross‑project value at the 2026 Stakeholder Forum

On 20 January, the GDI/B1MGplus Stakeholder Forum brought together representatives from European genomics and health data initiatives to take stock of how the Genomic Data Infrastructure (GDI) is supporting other EU projects, and what is needed to sustain that value after the current programme ends.

Held online and hosted by ELIXIR, the meeting focused on how GDI is aligning methods and services with the Genome of Europe, ERDERA, CANDLE and EUCAIM across population genomics, rare diseases, cancer research and AI-driven imaging.

Across the presentations and the closing panel discussion, the shared emphasis was on practical interoperability: making it easier for projects to connect to services, reduce duplication, and enable responsible reuse of data across borders and disciplines.

This discussion also situated GDI’s work in the wider context of Europe’s emerging Health Data Space, where sustained collaboration between infrastructures is expected to be essential for long-term impact.

A stronger spotlight on ERDERA’s contribution to rare disease research

ERDERA was discussed as a concrete example of how alignment with a European infrastructure can help address persistent barriers in rare disease research. Rare diseases often involve small and geographically dispersed patient populations, which makes data sharing and analysis across sites important for building sufficiently robust evidence.

Morris Swertz, Professor at University Medical Center Groningen (UMCG), set out how ERDERA is developing data sharing and analysis services and how these can be strengthened through interoperability with GDI. He described the value of approaches such as FAIR data catalogues and federated analysis, supported by secure analysis environments and high-performance computing, to enable collaboration while maintaining appropriate safeguards for sensitive data.

In this framing, the GDI–ERDERA collaboration is not an end in itself, but a means to make cross-border research more feasible in practice—helping rare disease researchers move from isolated datasets towards analyses that are better connected, more comparable and more reusable.

Outputs and next steps highlighted by the forum

The forum’s outputs centred on clarifying what GDI is already providing to other projects, how partner initiatives can benefit during the current phase, and what building blocks will be required to sustain and extend these services over time.

Participants also used the discussion to surface stakeholder questions and priorities, supporting a shared view of where alignment can be most actionable in the near term.

News & Updates

You might also be interested in

European Parliament research service assessment, published in February 2026, identifies 31 measures that could form an EU rare disease action plan, highlighting European Reference Networks and cross-border collaboration including ERDERA as drivers of EU added value.
This study investigates possible measures that could be taken at EU level to address these challenges. It finds significant European added value in harmonising coordination and access across the 27 Member States, mainly in terms of improved diagnostic tools and availability of medical treatment, better health outcomes, particularly lower infant mortality, and improved well-being of family members and caregivers.
28 February, across Europe and beyond: one year into delivery, ERDERA is advancing towards shorten diagnostic journeys and improved therapies for people living with a rare disease.
This meeting will focus on practical approaches to phenotyping and diagnosis in undiagnosed conditions, including how to define next steps when a diagnosis remains uncertain, and how to strengthen pathways and collaboration around undiagnosed care.